A recent publication in Science demonstrates the ability of prostate cancer cells to switch lineages from one that is dependent on androgen signaling to a cell type that is not. Known as lineage plasticity, this phenomenon is driven by the transcription factor SOX2 in RB1 and TP53-deficient prostate cancer. SOX2 is a potential prognostic marker and therapeutic target in castration resistant prostate cancer.
CITATION STYLE
Tuerff, D., Sissung, T., & Figg, W. D. (2017). Cellular identity crisis: Antiandrogen resistance by lineage plasticity. Cancer Biology and Therapy, 18(11), 841–842. https://doi.org/10.1080/15384047.2017.1323599
Mendeley helps you to discover research relevant for your work.